CR10024A - Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismos - Google Patents

Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismos

Info

Publication number
CR10024A
CR10024A CR10024A CR10024A CR10024A CR 10024 A CR10024 A CR 10024A CR 10024 A CR10024 A CR 10024A CR 10024 A CR10024 A CR 10024A CR 10024 A CR10024 A CR 10024A
Authority
CR
Costa Rica
Prior art keywords
egfr
vegf
methods
links
same
Prior art date
Application number
CR10024A
Other languages
English (en)
Inventor
Olga Ignatovich
Steve Holmes
Roland Beckmann
Haiqun Liu
Wildt Rudolf M T De
Laurent S Jespers
Michael Steward
Malgorzata Pupecka
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of CR10024A publication Critical patent/CR10024A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se dan a conocer ligandos que tienen especificidad de enlace para el factor de crecimiento endotelial vascular (VEGF), para el receptor del factor de crecimiento epidérmico (EGFR), o para VEGF y EGFR. También se dan a conocer métodos para utiliazar estos ligandos. En particular, se describe el uso de estos ligandos para la terapia de cáncer.
CR10024A 2005-12-06 2008-05-27 Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismos CR10024A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74299205P 2005-12-06 2005-12-06
US75835506P 2006-01-11 2006-01-11

Publications (1)

Publication Number Publication Date
CR10024A true CR10024A (es) 2008-09-22

Family

ID=37820653

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10024A CR10024A (es) 2005-12-06 2008-05-27 Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismos

Country Status (13)

Country Link
US (2) US20100056439A1 (es)
EP (1) EP1966242A1 (es)
JP (1) JP2009518024A (es)
KR (1) KR20080077261A (es)
AU (1) AU2006323412A1 (es)
BR (1) BRPI0619463A2 (es)
CA (1) CA2632417A1 (es)
CR (1) CR10024A (es)
EA (1) EA013878B1 (es)
MA (1) MA30021B1 (es)
NO (1) NO20082386L (es)
TW (1) TW200804425A (es)
WO (1) WO2007066106A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
GB0621513D0 (en) * 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
EP2222709B1 (en) * 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
TW200938222A (en) * 2007-12-13 2009-09-16 Glaxo Group Ltd Compositions for pulmonary delivery
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
KR20100132535A (ko) * 2008-03-31 2010-12-17 글락소 그룹 리미티드 약물 융합체 및 컨주게이트
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
EP2346526A2 (en) 2008-09-22 2011-07-27 Massachusetts Institute of Technology Compositions of and methods of using ligand dimers
JP2012506237A (ja) * 2008-10-21 2012-03-15 ドマンティス リミテッド Ｄｃ−ｓｉｇｎに対する結合特異性をもつリガンド
KR20110091777A (ko) * 2008-11-26 2011-08-12 글락소 그룹 리미티드 폴리펩티드, 항체 가변 도메인 및 길항제
WO2010081173A2 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
EA022925B1 (ru) * 2009-02-19 2016-03-31 Глаксо Груп Лимитед Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
US9394374B2 (en) * 2009-05-28 2016-07-19 Glaxo Group Limited Antigen-binding proteins
EP2454285A2 (en) * 2009-07-16 2012-05-23 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
SG188204A1 (en) * 2010-08-20 2013-04-30 Glaxo Group Ltd Improved anti-serum albumin binding variants
SG190362A1 (en) * 2010-11-24 2013-06-28 Glaxo Group Ltd Multispecific antigen binding proteins targeting hgf
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2777707A1 (en) 2013-03-11 2014-09-17 Wake Forest University Health Sciences Method of Treating Brain Tumors
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
PT3049439T (pt) * 2013-09-26 2020-03-31 Ablynx Nv Nanocorpos biespecíficos
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
WO2016127104A2 (en) * 2015-02-06 2016-08-11 University Of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
CN114106178A (zh) 2015-07-16 2022-03-01 印希比股份有限公司 多价和多特异性结合dr5的融合蛋白
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
EP3768722A4 (en) * 2018-03-19 2021-12-29 Wuxi Biologics Ireland Limited. Novel anti-egfr antibody polypeptide
CA3134680C (en) 2019-03-29 2024-02-06 Green Cross Corporation Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof
US12043652B2 (en) 2020-08-28 2024-07-23 Trustees Of Boston University Engineered extracellular receptor constructs and uses thereof
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2191702T3 (es) * 1994-03-17 2003-09-16 Merck Patent Gmbh Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
DE69735292T2 (de) * 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
IL132240A0 (en) * 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
CA2422881A1 (en) * 2000-10-13 2002-04-18 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
RU2430927C2 (ru) * 2000-10-20 2011-10-10 Тугаи Сейяку Кабусики Кайся Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1600459A3 (en) * 2002-06-28 2005-12-07 Domantis Limited Ligand
EP1558647B1 (en) * 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP2006523090A (ja) * 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
SI1639011T1 (sl) * 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
PT1687338E (pt) * 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US20090252681A1 (en) * 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR

Also Published As

Publication number Publication date
JP2009518024A (ja) 2009-05-07
EA013878B1 (ru) 2010-08-30
WO2007066106A1 (en) 2007-06-14
US20130041136A1 (en) 2013-02-14
TW200804425A (en) 2008-01-16
CA2632417A1 (en) 2007-06-14
US20100056439A1 (en) 2010-03-04
EP1966242A1 (en) 2008-09-10
KR20080077261A (ko) 2008-08-21
NO20082386L (no) 2008-08-27
EA200801172A1 (ru) 2008-12-30
BRPI0619463A2 (pt) 2013-01-08
AU2006323412A1 (en) 2007-06-14
MA30021B1 (fr) 2008-12-01

Similar Documents

Publication Publication Date Title
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
NO20082386L (no) Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav
CR9819A (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
GT200600407A (es) Compuestos ppar activos
CY1120267T1 (el) Αντισωματα ανταγωνιστες κατευθυνομενα εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης για την θεραπευτικη αγωγη αθροιστικης κεφαλαλγιας
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
DE602005021694D1 (de) Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung
CO6280498A2 (es) Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos
CR10530A (es) Anticuerpos anti-dlla4 y metodos que los usan
LTPA2017011I1 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
ECSP088508A (es) Antagonistas de neuropilina
ECSP088733A (es) Anticuerpos anti-5t4 y usos de los mismos
CO6290772A2 (es) Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
AR048006A1 (es) CONJUGADOS DE ALMIDON DE HIDROXIALQUILO Y UNA PROTEíNA
HN2005029978A (es) Formulaciones
ECSP099523A (es) Antagonistas específicos de VEGF para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadíos tempranos
WO2009009173A3 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
CY1111579T1 (el) Νεα συνδυασμενη χρηση μιας ενωσης σουλφοναμιδης (sulfonamide) στην θεραπεια του καρκινου
DK1951759T3 (da) Anti-EGFR-antistoffer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)